Document is current
Any future updates will be listed below
-
Authors
Vermandel, Maximilien
Dupont, Clément
Lecomte, Fabienne
Leroy, Henri-Arthur
Tuleasca, Constantin
Mordon, Serge
Hadjipanayis, Constantinos G.
Reyns, Nicolas https://orcid.org/0000-0002-1206-9342
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03048240 at ClinicalTrials.govDocuments that mention this clinical trial
Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial
https://doi.org/10.1007/s11060-021-03718-6
-
Funding
Funding for this research was provided by:
Agence Nationale pour la Recherche
Institut National de la Santé et de la Recherche Médicale
American Society for Laser Medicine and Surgery
university hospital of Lille
University of Lille
Ligue Contre le Cancer
- License Information
-
More Information
Article History
Received: 16 December 2020
Accepted: 13 February 2021
First Online: 20 March 2021
Declarations
:
: M. Vermandel, C. Dupont, S. Mordon and N. Reyns are co-founders of Hemerion Therapeutics SAS, Lille, France. Constantinos Hadjipanayis is a consultant for NX Development Corporation (NXDC) and Synaptive Medical Inc. He receives royalties from the sale of Gleolan® (5-ALA) which is marketed by NXDC. Gleolan® is an optical imaging agent approved in the United States for the visualization of malignant tissue during glioma surgery.
: All subjects signed a written informed consent form.
: All subject authorized the publication anonymously of their data.
: All procedures performed in studies were in accordance with the ethical standards of the National Research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The French National Agency for Medicine and Health Product Safety (ANSM) as well as the French National Ethics Committee approved this study.
